| |
|
|
A high-throughput protein array-based approach
Centre for Proteomic and Genomic Research
Here we present a novel discovery-oriented high-throughput approach to the screening of allergen reactivates in crude biological extracts is presented using seafood allergens as an example. The CPGR workflow permits the effective screening of hundreds of putative allergens in parallel using minute amounts of patient serum and constitutes a cost-efficient allergen-specific antibody screening method for a routine diagnostic setting.
|
Apoptosis Inducing Novel microRNA for Breast cancer and Hepatocellular Carcinoma
UC Davis Medical Center
MicroRNA provides a mechanism to target cancer stem cells and restraint tumors cells permanently; this could lead to promising cancer therapeutics and imaging agents. Apoptosis inducing microRNA was identified to target HCC and breast cancer cells for imaging and therapy.
|
A Novel Fluorimetric Assay for the Detection of TACE (a-Secretase)
AnaSpec, Inc.
To facilitate high throughput screening of TACE inhibitors, AnaSpec synthesized a novel peptide substrate for TACE using QXL™ 520/5-FAM FRET pair. Using this FRET substrate, AnaSpec developed a new kit – the SensoLyte™ 520 TACE Activity Assay. This kit can be used to detect the activity of the enzyme and for screening of TACE inhibitors. It is highly sensitive and can detect subnanogram amounts of enzyme.
|
|
|
|
|
|
Permanent Senior Scientist Position in NMR-based Metabolomics
CIBERDEM
Tarragona, Spain
|
|
|
BBSRC Funded Microfluidics Engineering Resarch PhD
University College London
London, UK
|
|
|
Post-Doctpral Position in Mollusk Health Laboratory
UPEI
Charlottetown, Canada
|
|
|
Production Chemist II
Independent
Torrance, CA, USA
|
|
|
Research Chemist
Independent
Torrance, CA, USA
|
|
|
phD Scholarship in BioInformatics
Universitat Rovira i Virgili
Tarragona, Spain
|
|
|
QC Analyst
Genomic Health
Redwood City, CA, USA
|
|
|
Research Scientist II - Biology
Gilead Sciences
Foster City, CA, USA
|
|
|
High Throughput Coordinator / Engineer
AJI
Houston, TX, USA
|
|
|
Assistant Director, Automation Services
Medarex, Inc.
Milpitas, CA, USA
|
|
|
|
3rd Annual Biomarkers Congress,14 & 15 May 2008, Manchester, UK
14 May 2008 - 15 May 2008
The conference programme will feature keynote addresses, case study presentations, panel and roundtable discussions from over 65 speakers in Biomarker Discovery and Validation, Molecular Diagnostics, Data Integration, Modelling and Bioinformatics, Imaging, Clinical Development and Toxicity Biomarkers.
|
IBC’s TIDES®: Oligonucleotide and Peptide® Technology and Product Development, Las Vegas, NV, USA
18 May 2008 - 21 May 2008
TIDES® is the all encompassing conference on manufacturing, formulation, delivery, process and analytical development, as well as overall market trends for peptides and oligonucleotides. In addition to gaining scientific updates in conference sessions, you can develop and maintain your professional skills with two tracks focusing on oligos and peptides.
|
Emerging Regulatory Issues in Genomic Medicine, Mexico City, Mexico
21 May 2008 - 23 May 2008
The purpose of this meeting is to identify synergies and common issues in Genomic Medicine and to develop common approaches to address these issues. The FDA has a major effort in the area of genomics and personalized medicine. It is working with clinicians, the pharmaceutical industry, and other regulatory agencies worldwide to integrate genomic medicine into medical practice
|
|
|
|
|
|
|
MicroRNA 2008
Published January 2008
This report presents an exhaustive analysis of all the products and services offered by the various vendors into the microRNA market. Select Biosciences' proprietary market surveys addressed the qualitative and quantitative trends in the microRNA research market in terms of challenges, opportunities, and quantitative industry metrics—all the raw data and analyses based on the data are presented. In addition to the microRNA research market, this report also addresses the industry dynamics/trends
|
RNAi Therapeutics 2008
Published November 2007
An exhaustive analysis of all the current RNAi therapeutics candidates in various clinical trial stages, a detailed market survey with a view of all therapeutic areas where RNAi therapeutics are expected to impact, drug targets amenable to RNAi therapeutics, druggability factors of RNAi-based therapeutics, a detailed analysis of technologies in RNAi, as well as the intellectual property (IP) landscape of RNAi-based therapeutics space.
|
|